Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts

Journal of Experimental Therapeutics and Oncology

Volumn 2, Issue 5, 2002, Pages 298-305

  Papadopoulou, Maria V ^a   Ji, Ming ^a   Bloomer, William D ^a   Hollingshead, Melinda G ^b  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Combined therapy; Cyclophosphamide; Hypoxic cytotoxins; NLCQ 1; PC 3 xenografts; SCCVII tumors

Indexed keywords

4 [3 (2 NITRO 1 IMIDAZOLYL)PROPYLAMINO] 7 CHLOROQUINOLINE; CYCLOPHOSPHAMIDE; CYTOTOXIN; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR GROWTH; WEIGHT REDUCTION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DRUG SYNERGISM; FEMALE; HUMANS; IMIDAZOLES; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; QUINOLINES; TRANSPLANTATION, HETEROLOGOUS;

EID: 0036733699     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1359-4117.2002.01054.x     Document Type: Article

References (46)

1. Hypoxia as a target for combined modality treatments
2. Hypoxia and radiation response in human tumors
3. Modification of chemotherapy by nitroimidazoles
4. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay
5. Relationship of hypoxia to metastatic ability in rodent tumours
6. Regulation of hypoxia-induced angiogenesis: A chaperone escorts VEGF to the dance
7. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
8. Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies
9. Bioreductive drugs into the next millennium
10. Enhancement of alkylating agent activity by SR-4233 in FSaIIC murine fibrosarcoma
11. Tumor-specific, schedule-dependent interaction between tirapazamine (SR4233) and cisplatin
12. Potentiation of antineoplastic drugs in vitro and in vivo by intercalating bioreductive agents
13. Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts
14. Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872
15. The in situ tumor response to combinations of cyclophosphamide and tirapazamine
16. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumors
17. THNLA-1 as radio/chemosensitizer of EMT6 tumors in mice
18. THNLA-1: A DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo
19. 9-[3-(2-Nitro-1-imidazolyl)-propylamino]cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): A novel DNA-affinic bioreductive agent as chemosensitizer. I
20. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine
21. Enhancement of the antitumor effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine
22. The chemopotentiation of cisplatin by the novel bioreductive drug AQ 4N
23. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer
24. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: A phase II study
25. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group
26. 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin
27. Hypoxia-selective antitumor agents: 8. Bis(nitroimidazolyl) alkanecarboxamides: A new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers
28. 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride ((NLCQ-1). A novel bioreductive agent as radiosensitizer in vitro and in vivo. Comparison with tirapazamine
29. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia
30. NLCQ-1, a novel hypoxic cytotoxin: Potentiation of melphalan, cisDDP and cyclophosphamide in vivo
31. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice
32. Potentiation of chemotherapeutic drugs by the bioreductive compound NLCQ-1 against SCCVII tumors in mice
33. Hypoxia-dependent retinal toxicity of NLCQ-1 and tirapazamine in BALB/c mice
34. Potentiation of combination chemotherapy by nitroheterocyclics
35. Human tumor xenograft models in NCI drug development
36. 3H]misonidazole binding and paired survival assay
37. Preclinical evaluation of fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for measurement of tumor hypoxia
38. 2 tension measurements
39. 2 tension measurements
40. 18F]fluoromisonidazole: A pretherapy study of 37 patients
41. Pretreatment oxygenation profiles of human soft tissue sarcomas
42. Oxygenation of head and neck tumors
43. Hypoxic regions exist in human prostate carcinoma
44. Radiobiological studies of PC-3 and DU-145 human prostate cancer cells: X-ray sensitivity in vitro and hypoxic fractions of xenografted tumors in vivo
45. Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro
46. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]-quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as chemosensitizer: Mechanistic studies. II